Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4130
Source ID: NCT00399724
Associated Drug: Insulin Glargine
Title: A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
Acronym: AT-LANTUS
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Insulin glargine
Outcome Measures: Primary: Incidence of severe hypoglycaemia | Secondary: Incidence of any hypoglycaemia|Incidence of symptomatic hypoglycaemia|Incidence of nocturnal hypoglycaemia|Incidence of asymptomatic hypoglycaemia|Adjusted mean change in Hb1Ac (%)|Adjusted mean change in fasting blood glucose (FBG) (mg/dl)|Adjusted mean change in nocturnal blood glucose (NBG) (mg/dl)|Adjusted mean change in mean daily blood glucose (MBG) (mg/dl)|% of subjects at v12 with Hb1Ac < or = 6.5 %|% of subjects at v12 with Hb1Ac < or = 7.0 %|% of subjects at v12 with FBG < or = 100 mg/dl|Weight change (kg)|Change in insulin glargine dose v2 - v12 (IU)|Safety data|Quality of Life and treatment satisfaction before, during and at the end of treatment using the Diabetes Treatment Satisfaction Questionnaire
Sponsor/Collaborators: Sponsor: Sanofi
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 7376
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2002-03
Completion Date: 2003-08
Results First Posted:
Last Update Posted: 2010-08-31
Locations:
URL: https://clinicaltrials.gov/show/NCT00399724